<DOC>
	<DOCNO>NCT00904449</DOCNO>
	<brief_summary>The purpose study monitor long-term analgesic effectiveness , safety , utility oxymorphone ER relief moderate severe pain due cancer .</brief_summary>
	<brief_title>Open Label Assessment Long-Term Safety Utility</brief_title>
	<detailed_description />
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>Males female age &gt; 18 year moderate severe pain arise cancer ( histologically and/or clinically prove ) require chronic treatment WHO step 3 analgesic . Women childbearing potential must use approve method contraception ( hormone contraception , IUD , double barrier method ) negative serum pregnancy test prior entry study . Participated study EN3202018 ; patient must treat study medication complete exit visit eligible . Experienced serious , adverse experience study EN3202018 possible probably related study medication . Withdrew study EN3202018 due Adverse experience possibly probably relate study medication . Known idiosyncratic reaction hypersensitivity oxymorphone . Inability take oral medication 1 week . Patients ileosomy , mechanical intestinal obstruction , partial complete gastric outlet obstruction , parlayticileus , condition might contraindicate use , impair absorption oral controlledrelease dosage form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>